Budipine
Top View
- Edward M. Sellers, S. Victoria Otton, and Rachel F. Tyndale
- 2U11/148243 Al
- New Molecular Targets for Antidepressant Drugs
- Pharmacodynamics of Memantine: an Update G
- Parkinson's Disease in the United States
- Which PCP-Like NMDA-Receptor Antagonists Are Available for Clinical
- Wo 2007/044693 A2
- What Drugs Might Affect the Interpretation of Datscan? Appraised by Kevin Galbraith, 9 February 2016 Update Due 2019
- The Investigation of the Antiparkinsonian Effects of Glutamate Receptor Antagonists
- The Role of the NMDA Receptors and L-Arginine–Nitric Oxide–Cyclic
- Bromocriptine Mesilate/Budipine
- (12) United States Patent (10) Patent No.: US 8,889,740 B1 Went Et Al
- (12) United States Patent (10) Patent No.: US 8,329,752 B2 Went Et Al
- Therapeutic and Toxic Blood Concentrations of More Than 1100 Drugs and Other Xenobiotics
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Problems of Drug Dependence 1995: Proceedings of the 57Th Annual Scientific Meeting the College on Problems of Drug Dependence, Inc
- Amantadine Hcl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson’S Disease Patients (Ease Lid Study)
- Emulated Clinical Trials from Longitudinal Real-World